Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy

NCT01652560 is registered in ClinicalTrials.gov with LiNanlin,Ph.D, Chief Physician,Clinical Professor as lead sponsor.

NCT NCT01652560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01652560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy
Lead sponsor
LiNanlin,Ph.D, Chief Physician,Clinical Professor
Phase
Observational
Overall status
Unknown status
Start date
June 30, 2012
Completion date
September 30, 2014
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bevacizumab, breast cancer, molecular targeted therapy, neoadjuvant chemotherapy